Systemic therapy in advanced hepatocellular carcinoma

키워드

참고문헌 (27)

1. Yang JD, "New advances in the diagnosis and management of hepatocellular carcinoma", BMJ, 371, pp.m3544~ (2020)
2. Yang C, "Evolving therapeutic landscape of advanced hepatocellular carcinoma", Nat Rev Gastroenterol Hepatol (2022)[DOI]
3. Llovet JM, "Sorafenib in advanced hepatocellular carcinoma", N Engl J Med, 359, pp.378~390 (2008)
4. Kudo M, "Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma : a randomised phase 3non-inferiority trial", Lancet, 391, pp.1163~1173 (2018)
5. Bruix J, "Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial", Lancet, 389, pp.56~66 (2017)
6. Abou-Alfa GK, "Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma", N Engl J Med, 379, pp.54~63 (2018)
7. Zhu AX, "Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial", Lancet Oncol, 20, pp.282~296 (2019)
8. Qin S, "Donafenib versus sorafenib in first-line treatment of unresectable or metastatic hepatocellular carcinoma : a randomized, open-label, parallelcontrolled phase II-III trial", J Clin Oncol, 39, pp.3002~3011 (2021)
9. Qin S, "Apatinib as secondline or later therapy in patients with advanced hepatocellular carcinoma(AHELP) : a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial", Lancet Gastroenterol Hepatol, 6, pp.559~568 (2021)
10. El-Khoueiry AB, "Impact of antitumor activity on survival outcomes, and nonconventional benefit, with nivolumab(NIVO)in patients with advanced hepatocellular carcinoma(aHCC) : Subanalyses of CheckMate-040", J Clin Oncol, 36(4 suppl), pp.475~ (2018)
11. Zhu AX, "Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial", Lancet Oncol, 19, pp.940~952 (2018)
12. Qin S, "Final analysis of RATIONALE-301 : Randomized, phase III study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma", Ann Oncol, 33(Suppl 7), pp.S1402~S1403 (2022)
13. Finn RS, "Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma", N Engl J Med, 382, pp.1894~1905 (2020)
14. Cheng AL, "Updated efficacy and safety data from IMbrave150 : Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma", J Hepatol, 76, pp.862~873 (2022)
15. Gordan JD, "Systemic therapy for advanced hepatocellular carcinoma : ASCO guideline", J Clin Oncol, 38, pp.4317~4345 (2020)
16. Reig M, "BCLC strategy for prognosis prediction and treatment recommendation : The 2022 update", J Hepatol, 76, pp.681~693 (2022)
17. Llovet JM, "Trial design and endpoints in hepatocellular carcinoma: AASLD consensus conference", Hepatology, 73(Suppl 1), pp.158~191 (2021)
18. Maker AV, "Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade", J Immunol, 175, pp.7746~7754 (2005)
19. Yau T, "Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: The CheckMate 040 randomized clinical trial", JAMA Oncol, 6, pp.e204564~ (2020)
20. Abou-Alfa GK, "Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma", NEJM Evidence, 1, pp.EVIDoa2100070~ (2022)
21. Kelley RK, "Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma(COSMIC-312) : a multicentre, openlabel, randomised, phase 3 trial", Lancet Oncol, 23, pp.995~1008 (2022)
22. R.S. Finn MK, "Pembrolizumab", lenvatinib combo misses survival end points in unresectable HCC, 2022, pp.33(Suppl 7), S1808~S869
23. Ren Z, "Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study", Lancet Oncol, 22, pp.977~990 (2021)
24. Qin S, "Camrelizumab(C)plus rivoceranib(R)vs. sorafenib(S)as first-line therapy for unresectable hepatocellular carcinoma(uHCC) : A randomized, phase III trial", Ann Oncol, 33(Suppl 7), pp.S1401~S1402 (2022)
25. Llovet JM, "Randomized phase 3 LEAP-012 study : transarterial chemoembolization with or without lenvatinib plus pembrolizumab for intermediate-stage hepatocellular carcinoma not amenable to curative treatment", Cardiovasc Intervent Radiol, 45, pp.405~412 (2022)
26. Tai D, "Radioembolisation with Y90-resin microspheres followed by nivolumab for advanced hepatocellular carcinoma(CA 209-678) : a single arm, single centre, phase 2 trial", Lancet Gastroenterol Hepatol, 6, pp.1025~1035 (2021)
27. Dawson LA, "NRG", RTOG 1112 : Randomized phase III study of sorafenib vs. stereotactic body radiation therapy(SBRT)followed by sorafenib in hepatocellular carcinoma(HCC), 2023, pp.41(4 suppl), 489~

관련 논문AI추천